Enzo Biochem Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.34
- Today's High:
- $1.43
- Open Price:
- $1.43
- 52W Low:
- $1
- 52W High:
- $2.7497
- Prev. Close:
- $1.45
- Volume:
- 185954
Company Statistics
- Market Cap.:
- $109.90 million
- Book Value:
- 0.674
- Revenue TTM:
- $81.12 million
- Operating Margin TTM:
- -45.91%
- Gross Profit TTM:
- $41.97 million
- Profit Margin:
- -43.44%
- Return on Assets TTM:
- -25.13%
- Return on Equity TTM:
- -71.96%
Company Profile
Enzo Biochem Inc had its IPO on 1980-06-12 under the ticker symbol ENZ.
The company operates in the Healthcare sector and Diagnostics & Research industry. Enzo Biochem Inc has a staff strength of 465 employees.
Stock update
Shares of Enzo Biochem Inc opened at $1.43 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.34 - $1.43, and closed at $1.34.
This is a -7.59% slip from the previous day's closing price.
A total volume of 185,954 shares were traded at the close of the day’s session.
In the last one week, shares of Enzo Biochem Inc have slipped by -13.55%.
Enzo Biochem Inc's Key Ratios
Enzo Biochem Inc has a market cap of $109.90 million, indicating a price to book ratio of 1.3645 and a price to sales ratio of 0.5719.
In the last 12-months Enzo Biochem Inc’s revenue was $81.12 million with a gross profit of $41.97 million and an EBITDA of $-34395000. The EBITDA ratio measures Enzo Biochem Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Enzo Biochem Inc’s operating margin was -45.91% while its return on assets stood at -25.13% with a return of equity of -71.96%.
In Q0.33333333333333, Enzo Biochem Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 52%.
Enzo Biochem Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enzo Biochem Inc’s profitability.
Enzo Biochem Inc stock is trading at a EV to sales ratio of 0.6956 and a EV to EBITDA ratio of -3.2938. Its price to sales ratio in the trailing 12-months stood at 0.5719.
Enzo Biochem Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $76.45 million
- Total Liabilities
- $32.20 million
- Operating Cash Flow
- $-869000.00
- Capital Expenditure
- $869000
- Dividend Payout Ratio
- 0%
Enzo Biochem Inc ended 2024 with $76.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $76.45 million while shareholder equity stood at $32.83 million.
Enzo Biochem Inc ended 2024 with $0 in deferred long-term liabilities, $32.20 million in other current liabilities, 487000.00 in common stock, $-310593000.00 in retained earnings and $7.45 million in goodwill. Its cash balance stood at $5.05 million and cash and short-term investments were $5.05 million. The company’s total short-term debt was $7,187,000 while long-term debt stood at $289000.00.
Enzo Biochem Inc’s total current assets stands at $36.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $10.87 million compared to accounts payable of $13.19 million and inventory worth $15.72 million.
In 2024, Enzo Biochem Inc's operating cash flow was $-869000.00 while its capital expenditure stood at $869000.
Comparatively, Enzo Biochem Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.34
- 52-Week High
- $2.7497
- 52-Week Low
- $1
- Analyst Target Price
- $
Enzo Biochem Inc stock is currently trading at $1.34 per share. It touched a 52-week high of $2.7497 and a 52-week low of $2.7497. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.54 and 200-day moving average was $1.77 The short ratio stood at 6.81 indicating a short percent outstanding of 0%.
Around 2174.7% of the company’s stock are held by insiders while 4087.6% are held by institutions.
Frequently Asked Questions About Enzo Biochem Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing “STAT’ or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.